eMedicine Specialties > Cardiology > Arrhythmias
Paroxysmal Supraventricular Tachycardia
Updated: Aug 12, 2009
Introduction
Background
Supraventricular tachycardia (SVT), a common clinical condition, is any tachyarrhythmia that requires atrial and/or atrioventricular (AV) nodal tissue for its initiation and maintenance. It is usually a narrow-complex tachycardia that has a regular, rapid rhythm; exceptions include atrial fibrillation (AF) and multifocal atrial tachycardia (MAT). Aberrant conduction during SVT results in a wide-complex tachycardia. SVT occurs in persons of all age groups, and treatment can be challenging.
Paroxysmal supraventricular tachycardia (PSVT) is episodic, with an abrupt onset and termination. Manifestations of SVT are quite variable; patients may be asymptomatic or they may present with minor palpitations or more severe symptoms. Results from electrophysiology studies have helped determine that the pathophysiology of SVT involves abnormalities in impulse formation and conduction pathways. The most common mechanism identified is reentry.15,41,3,50 This article focuses on SVT, including the pathophysiology, clinical presentation, diagnosis, management, and treatment options of this condition.
Pathophysiology
The development of intracardiac electrophysiology studies has dramatically changed the classification of SVT. Intracardiac recordings have identified the various mechanisms of SVT. Depending on the site of origin of the dysrhythmia, SVTs may be classified as an atrial or AV tachyarrhythmia.27,7
Atrial tachyarrhythmias include (1) sinus tachycardia, (2) inappropriate sinus tachycardia (IST), (3) sinus nodal reentrant tachycardia (SNRT), (4) atrial tachycardia, (5) multifocal atrial tachycardia, (6) atrial flutter, and (7) atrial fibrillation.
AV tachyarrhythmias include (1) AV nodal reentrant tachycardia (AVNRT), (2) AV reentrant tachycardia (AVRT), (3), junctional ectopic tachycardia (JET), and (4) nonparoxysmal junctional tachycardia (NPJT).
Atrial Tachyarrhythmias
Sinus tachycardia
Sinus tachycardia is an accelerated sinus rate that is a physiologic response to a stressor. It is characterized by a heart rate faster than 100 beats per minute (bpm) and generally involves a regular rhythm (see Media file 1). Underlying physiological stresses such as hypoxia, hypovolemia, fever, anxiety, pain, hyperthyroidism, and exercise usually induce sinus tachycardia.47,19 Treatment involves addressing the basic underlying stressor. Certain drugs, such as stimulants (eg, nicotine, caffeine), medications (eg, atropine, salbutamol), recreational drugs (eg, cocaine, amphetamines, ecstasy), and hydralazine, can also induce sinus tachycardia.
Sinus tachycardia. Note that the QRS complexes are narrow and regular. The patient's heart rate is approximately 135 bpm. P waves are normal in morphology.
Inappropriate sinus tachycardia
IST is an accelerated baseline sinus rate in the absence of a physiological stressor. In this situation, healthy adults may have an elevated resting heart rate and an exaggerated heart rate response to even minimal exercise. This tachyarrhythmia is observed most commonly in young women without structural heart disease.8,29,55 The underlying mechanism of IST may be hypersensitivity of the sinus node to autonomic input or an abnormality within the sinus node, its autonomic input, or both.8,29,55
Sinus nodal reentrant tachycardia
SNRT is frequently confused with IST. SNRT is due to a reentry circuit, either in or near the sinus node. Therefore, it has an abrupt onset and offset. The heart rate is usually 100-150 bpm, and ECG tracings usually demonstrate normal sinus P-wave morphology.8,29,55
Atrial tachycardia
Atrial tachycardia is an arrhythmia originating in the atrial myocardium. Enhanced automaticity, triggered activity, or reentry may result in this rare tachycardia.51,17,10,30,55 The heart rate is regular and is usually 120-250 bpm. The P-wave morphology is different from the sinus P waves and is dependent on the site of origin of the tachycardia (see Media file 2). Because the arrhythmia does not involve the AV node, nodal blocking agents such as adenosine and verapamil are usually unsuccessful in terminating this arrhythmia. Atrial tachycardia has also been associated with digoxin toxicity via the triggered mechanism.51,17,10,30,55
Atrial tachycardia. The patient's heart rate is 151 bpm. P waves are upright in lead V1.
Multifocal atrial tachycardia
Multifocal atrial tachycardia is a tachyarrhythmia that arises within the atrial tissue; it is composed of 3 or more P-wave morphologies and heart rates. This arrhythmia is fairly uncommon and is typically observed in elderly patients with pulmonary disease. The heart rate is greater than 100 bpm, and ECG findings typically include an irregular rhythm, which may be misinterpreted as atrial fibrillation (see Media file 3). Treatment involves correcting the underlying disease process.38,22,43 Magnesium and verapamil may sometimes be effective.
Multifocal atrial tachycardia. Note the different P-wave morphologies and irregularly irregular ventricular response.
Atrial flutter
Atrial flutter is a tachyarrhythmia arising above the AV node with an atrial rate of 250-350 bpm. The mechanism behind atrial flutter is generally reentrant in nature. Typically, counterclockwise atrial flutter is due to a macroreentrant right atrial circuit. It is commonly observed in patients with ischemic heart disease, myocardial infarction, cardiomyopathy, myocarditis, pulmonary embolus, toxic ingestion (eg, alcohol), or chest trauma. It may be a transitional rhythm and can progress to atrial fibrillation. ECG findings of typical atrial flutter include negative sawtooth flutter waves in leads II, III, and aVF. AV conduction is most commonly 2:1, which yields a ventricular rate of approximately 150 bpm (see Media file 4).2,47,24
Atrial flutter. The patient's heart rate is approximately 135 bpm with 2:1 conduction. Note the sawtooth pattern formed by the flutter waves.
Atrial fibrillation
Atrial fibrillation is an extremely common arrhythmia arising from chaotic atrial depolarization. The atrial rate is usually 300-600 bpm, while the ventricular rate may be 170 bpm or more. ECG findings characteristically include an irregular rhythm with fibrillatory atrial activity (see Media file 5). This arrhythmia is associated with rheumatic heart disease, hypertension, ischemic heart disease, pericarditis, thyrotoxicosis, alcohol intoxication, mitral valve prolapse and other disorders of the mitral valve, and digitalis toxicity.2,47,24 When atrial fibrillation occurs in young or middle-aged patients in the absence of structural heart disease or any apparent cause, it is called lone or idiopathic atrial fibrillation.
Atrial fibrillation. The patient's ventricular rate varies from 130-168 bpm. Rhythm is irregularly irregular. P waves are not discernible.
AV Tachyarrhythmias
AV nodal reentrant tachycardia
The most common cause of paroxysmal supraventricular tachycardia is AVNRT. AVNRT is diagnosed in 50-60% of patients who present with regular narrow QRS tachyarrhythmia.25,2,23,3 The heart rate is 120-250 bpm and is typically quite regular (see Media files 6-7). AVNRT may occur in healthy, young individuals, and it occurs most commonly in women.23 Most patients do not have structural heart disease. However, occasionally these individuals may have an underlying heart condition such as rheumatic heart disease, pericarditis, myocardial infarction, mitral valve prolapse, or preexcitation syndrome.25,3,23,3
Atrioventricular nodal reentrant tachycardia. The patient's heart rate is approximately 146 bpm with a normal axis. Note the pseudo S waves in leads II, III, and aVF. Also note the pseudo R' waves in V1 and aVR. These deflections represent retrograde atrial activation.
Same patient as in Media file 6. Patient is in sinus rhythm following atrioventricular nodal reentrant tachycardia.
An understanding of the electrophysiology of AV nodal tissue is very important in order to comprehend the mechanism of AVNRT. In most people, the AV node has a single conducting pathway that conducts impulses in an anterograde manner to depolarize the bundle of His. In certain cases, AV nodal tissue may have 2 conducting pathways with different electrophysiological properties (see Media file 8). One pathway (alpha) is a relatively slow conducting pathway with a short refractory period, while the second pathway (beta) is a rapid conducting pathway with a long refractory period. The coexistence of these functionally different pathways serves as the substrate for reentrant tachycardia.25,2,3,20 Electrophysiologic studies have demonstrated dual AV nodal pathways in 40% of patients.
Onset of AVNRT is triggered by a premature atrial impulse. A premature atrial impulse may reach the AV node when the fast pathway (beta) is still refractory from the previous impulse but the slow pathway (alpha) may be able to conduct. The premature impulse then conducts through the slow pathway (alpha) in an anterograde manner; the (beta) pathway continues to recover because of its longer refractory period. After the impulse conducts in an anterograde manner through the slow (alpha) pathway, it may find the fast (beta) pathway recovered; the impulse then conducts in a retrograde manner via the fast (beta) pathway. If the slow pathway (alpha) has repolarized by the time the impulse completes the retrograde conduction, the impulse can then reenter the slow (alpha) pathway and initiate AVNRT (see Media file 8).
Image A displays the slow pathway and the fast pathway, with a regular impulse being conducted through the atrioventricular node. Image B displays a premature impulse that is conducted in an anterograde manner through the slow pathway and in a retrograde manner through the fast pathway, as is seen in typical atrioventricular nodal tachycardia. Image C displays the premature impulse conducting in a retrograde manner through the pathway and the impulse reentering the pathway with anterograde conduction, which is seen commonly in patients with atypical atrioventricular nodal tachycardia.
Importantly, note that AVNRT does not involve the ventricles as part of the reentry circuit; the necessity of perinodal atrial tissue to the circuit is controversial. Because the impulse typically conducts in an anterograde manner through the slow pathway and in a retrograde manner through the fast pathway, the PR interval is longer than the RP interval. Thus, in patients with typical AVNRT, the P wave is usually located at the terminal portion of the QRS complex.25,3,2,20,24 In patients with atypical AVNRT, anterograde conduction is via the fast pathway, while retrograde conduction is via the slow pathway. For these atypical patients, the RP interval is longer than the PR interval.25,54,2,23,3,20,26,24
AV reentrant tachycardia
AVRT is the second most common form of paroxysmal supraventricular tachycardia. The incidence rate of AVRT in the general population is 0.1-0.3%. AVRT is more common in males than in females (male-to-female ratio of 2:1), and patients with AVRT commonly present at a younger age than patients with AVNRT. AVRT is associated with the Ebstein anomaly, although most patients with AVRT do not have evidence of structural heart disease. AVRT occurs in the presence of accessory pathways, or bypass tracts. Accessory pathways are errant strands of myocardium that bridge the mitral or tricuspid valves.25,33,20,55
AVRT is the result of 2 or more conducting pathways: the AV node and 1 or more bypass tracts. In a normal heart, only a single route of conduction is present. Conduction begins at the sinus node, progresses to the AV node, and then to the bundle of His and the bundle branches. However, in AVRT, 1 or more accessory pathways connect the atria and the ventricles. The accessory pathways may conduct impulses in an anterograde manner, a retrograde manner, or both.52,14,25,18,33,37,20,55 When impulses travel down the accessory pathway in an anterograde manner, ventricular preexcitation results. This produces a short PR interval and a delta wave as is observed in persons with Wolff-Parkinson-White (WPW) syndrome (see Media file 9).52
Wolff-Parkinson-White pattern. Note the short PR interval and slurred upstroke (delta wave) to the QRS complexes.
Importantly, note that not all accessory pathways conduct in an anterograde manner. Concealed accessory pathways are not evident during sinus rhythm, and they are only capable of retrograde conduction. A reentry circuit is most commonly established by impulses traveling in an anterograde manner through the AV node and in a retrograde manner through the accessory pathway; this is called orthodromic AVRT. A reentry circuit may also be established by a premature impulse traveling in an anterograde manner through a manifest accessory pathway and in a retrograde manner through the AV node; this is called antidromic AVRT (see Media file 10).6,34
The left image displays the atrioventricular node with the accessory pathway. The impulse is conducted in an anterograde manner in the atrioventricular node and in a retrograde manner in the accessory pathway. This circuit is known as orthodromic atrioventricular reentrant tachycardia and can occur in patients with concealed accessory tracts or Wolff-Parkinson-White syndrome. The right image displays the impulse being conducted in an anterograde manner through the accessory pathway and in a retrograde manner via the atrioventricular node. This type of circuit is known as antidromic atrioventricular reentrant tachycardia and only occurs in patients with Wolff-Parkinson-White syndrome. Both patterns may display retrograde P waves after the QRS complexes.
While the orthodromic AVRT is typically a narrow-complex tachycardia (see Media file 11), antidromic AVRT inscribes a bizarre, wide-complex tachycardia (see Media file 12).6,5,34
Orthodromic atrioventricular reentrant tachycardia. This patient has Wolff-Parkinson-White syndrome.
The left panel depicts antidromic atrioventricular reentrant tachycardia. The right panel depicts sinus rhythm in a patient with antidromic atrioventricular reentrant tachycardia. Note that the QRS complex is an exaggeration of the delta wave during sinus rhythm.
Patients with Wolff-Parkinson-White syndrome can develop atrial fibrillation and atrial flutter (see Media file 13). The rapid nondecremental conduction via the accessory pathways can result in extremely rapid rates, which can degenerate to ventricular fibrillation and cause sudden death. Patients with preexcitation syndromes with atrial fibrillation must not be administered an AV nodal blocking agent; these agents can further increase conduction via the accessory pathway, which increases the risk of ventricular fibrillation and death.11,46,28,6,49,32,35
Atrial fibrillation in a patient with Wolff-Parkinson-White syndrome. Note the extremely rapid ventricular rate and variability in QRS morphology. Several minutes later, the patient developed ventricular fibrillation.
Junctional ectopic tachycardia and nonparoxysmal junctional tachycardia
JET and NPJT are rare and presumably arise because of increased automaticity, triggered activity, or both. They are usually observed following valvular surgery, after myocardial infarction, during active rheumatic carditis, or with digoxin toxicity. These tachycardias are also observed in children following congenital heart surgery. ECG findings include a regular narrow QRS complex, although P waves may not be visible. Patients with AV dissociation have also been described.20,39,48
Frequency
International
Paroxysmal supraventricular tachycardia incidence is approximately 1-3 cases per 1000 persons. The incidence rate of the WPW pattern on ECG tracings is 0.1-0.3% in the general population, although not all patients develop SVT.28,32,20,55,4 In a population-based study, the prevalence of paroxysmal supraventricular tachycardia was 2.25 cases per 1000 persons, with an incidence of 35 cases per 100,000 person-years.36 AVNRT is more common in patients who are of middle age or older, while adolescents are more likely to have SVT mediated by an accessory pathway. Paroxysmal supraventricular tachycardia is not only observed in healthy individuals, it is also common in patients with previous myocardial infarction, mitral valve prolapse, rheumatic heart disease, pericarditis, pneumonia, chronic lung disease, and current alcohol intoxication.28,32,20,55 Digoxin toxicity also may be associated with paroxysmal supraventricular tachycardia.20,55,24
Mortality/Morbidity
- Paroxysmal supraventricular tachycardia may start suddenly and last for seconds or days. Patients may or may not be symptomatic, depending on their hemodynamic reserve and their heart rate, the duration of the paroxysmal supraventricular tachycardia, and coexisting diseases. Paroxysmal supraventricular tachycardia can result in heart failure, pulmonary edema, myocardial ischemia, and/or myocardial infarction secondary to an increased heart rate in patients with poor left ventricular function.20,55,24 In fact, one study found that one third of patients with SVT experienced syncope, required cardioversion, or had an episode of sudden death.53 Incessant SVT can cause tachycardia-induced cardiomyopathy.
- Patients with WPW syndrome may be at risk for cardiac arrest if they develop atrial fibrillation or atrial flutter in the presence of a rapidly conducting (ie, short anterograde refractory period) accessory pathway. Extremely rapid ventricular rates during atrial fibrillation or atrial flutter can cause deterioration to ventricular fibrillation. This complication is unusual and occurs primarily in patients who have had prior symptoms due to WPW syndrome. In rare cases, sudden death may be the initial presentation of WPW syndrome.
- In the absence of manifest preexcitation (ie, WPW syndrome), the risk of sudden death with paroxysmal supraventricular tachycardia is extremely small.
Race
No known racial differences exist regarding the incidence or presentation of paroxysmal supraventricular tachycardia.
Sex
- Most series of catheter ablation reflect a higher proportion of female patients with AVNRT than male patients. This may reflect a true higher incidence in women, or it may reflect the sample of patients who are referred (or choose) to undergo extensive evaluation and/or catheter ablation.
- In a population-based study, the risk of developing paroxysmal supraventricular tachycardia was twice as high in women compared to men.36
Age
- The prevalence of paroxysmal supraventricular tachycardia increases with age.36
- The relative frequency of tachycardia mediated by an accessory pathway decreases with age.
Clinical
History
- Because symptom severity depends on the presence of structural heart disease and on the hemodynamic reserve of the patient, individuals with paroxysmal supraventricular tachycardia may present with mild symptoms or severe cardiopulmonary complaints. Some common presenting symptoms are listed below.53,4 Palpitations and dizziness are the most common symptoms reported by patients with SVT. Chest discomfort may be secondary to a rapid heart rate, and it frequently subsides with the termination of the tachycardia. Persistent SVT may lead to tachycardia-induced cardiomyopathy.
- Common presenting symptoms of paroxysmal supraventricular tachycardia and their frequency rates are as follows:
- Palpitation - Greater than 96%
- Dizziness - 75%
- Shortness of breath - 47%
- Syncope - 20%
- Chest pain - 35%
- Fatigue - 23%
- Diaphoresis - 17%
- Nausea - 13%
- History should include time of onset, any triggers, any previous episodes or arrhythmia, and previous treatment. A detailed past medical and cardiac history and a complete list of all medications should be obtained.
- Patients who are hemodynamically unstable should be resuscitated immediately with cardioversion. An ECG should be performed as soon as possible.
- Many patients with frequent episodes of paroxysmal supraventricular tachycardia tend to avoid activities such as exercising and driving due to past episodes of syncope or near-syncope.
Physical
- Pertinent findings are generally limited to cardiovascular and respiratory systems. Patients often appear quite distressed. Tachycardia may be the only finding in patients who are otherwise healthy and have significant hemodynamic reserve.
- Patients who have limited hemodynamic reserve may be tachypneic and hypotensive. Crackles may be auscultated secondary to heart failure. An S3 may be present, and large jugular venous pulsations may also be visualized.20,53,55
Causes
Supraventricular tachycardia or paroxysmal supraventricular tachycardia are triggered by reentry mechanism. This may be induced by premature atrial or ventricular ectopic beats. Other triggers include hyperthyroidism and stimulants, including caffeine, drugs, and alcohol.
More on Paroxysmal Supraventricular Tachycardia |
 Overview: Paroxysmal Supraventricular Tachycardia |
| Differential Diagnoses & Workup: Paroxysmal Supraventricular Tachycardia |
| Treatment & Medication: Paroxysmal Supraventricular Tachycardia |
| Follow-up: Paroxysmal Supraventricular Tachycardia |
| Multimedia: Paroxysmal Supraventricular Tachycardia |
| References |
| Next Page » |
References
[Guideline] Advanced cardiovascular life support, Introduction to ACLS 2000. Overview of recommended changes in ACLS from Guidelines 2000 Conference. Circulation. 2000;102:186-189.
Akhtar M. Supraventricular tachycardias. Electrophysiologic mechanisms: Diagnosis and pharmacological therapy. In: Josephson ME, Wellens HJ, eds. Tachycardias: Mechanisms, Diagnosis, Treatment. Philadelphia, Pa: Lea & Febiger; 1984:137.
Akhtar M, Jazayeri MR, Sra J, Blanck Z, Deshpande S, Dhala A. Atrioventricular nodal reentry. Clinical, electrophysiological, and therapeutic considerations. Circulation. Jul 1993;88(1):282-95. [Medline].
Al-Khatib SM, Pritchett EL. Clinical features of Wolff-Parkinson-White syndrome. Am Heart J. Sep 1999;138(3 Pt 1):403-13. [Medline].
Atie J, Brugada P, Brugada J, et al. Clinical and electrophysiologic characteristics of patients with antidromic circus movement tachycardia in the Wolff-Parkinson-White syndrome. Am J Cardiol. Nov 1 1990;66(15):1082-91. [Medline].
Bardy GH, Packer DL, German LD, Gallagher JJ. Preexcited reciprocating tachycardia in patients with Wolff-Parkinson-White syndrome: incidence and mechanisms. Circulation. Sep 1984;70(3):377-91. [Medline].
Basta M, Klein GJ, Yee R, Krahn A, Lee J. Current role of pharmacologic therapy for patients with paroxysmal supraventricular tachycardia. Cardiol Clin. Nov 1997;15(4):587-97. [Medline].
Bellet S. Clinical Disorders of the Heart Beat. Philadelphia, Pa: Lea & Febiger; 1963:144-5.
[Guideline] Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol. Oct 15 2003;42(8):1493-531. [Medline].
Brugada P, Wellens HJ. The role of triggered activity in clinical ventricular arrhythmias. Pacing Clin Electrophysiol. Mar 1984;7(2):260-71. [Medline].
Campbell RW, Smith RA, Gallagher JJ, Pritchett EL, Wallace AG. Atrial fibrillation in the preexcitation syndrome. Am J Cardiol. Oct 1977;40(4):514-20. [Medline].
Campbell RW. Supraventricular tachycardia. Doing the right things. Eur Heart J. May 1997;18 Suppl C:C50-3. [Medline].
Connors S, Dorian P. Management of supraventricular tachycardia in the emergency department. Can J Cardiol. Mar 1997;13 Suppl A:19A-24A. [Medline].
Coumel P, Gourgon R, Fabiato A, Laurent D, Bouvrain Y. [Studies of assisted circulation. I. Methods of repetitive provoked extrasystole and slowing of effective heart rate]. Arch Mal Coeur Vaiss. Jan 1967;60(1):67-88. [Medline].
Denes P, Wu D, Dhingra RC, Chuquimia R, Rosen KM. Demonstration of dual A-V nodal pathways in patients with paroxysmal supraventricular tachycardia. Circulation. Sep 1973;48(3):549-55. [Medline].
Etheridge SP, Judd VE. Supraventricular tachycardia in infancy: evaluation, management, and follow-up. Arch Pediatr Adolesc Med. Mar 1999;153(3):267-71. [Medline].
Farre J, Wellens HJ. The value of the electrocardiogram in diagnosing site of origin and mechanism of supraventricular tachycardia. In: Wellens HJJ, Kulbetus HE, eds. What's New in Electrocardiography. The Hague, Belgium; Martinus Nijhoff; 1981:131-71.
Gallagher JJ, Sealy WC. The permanent form of junctional reciprocating tachycardia: further elucidation of the underlying mechanism. Eur J Cardiol. Nov 1978;8(4-5):413-30. [Medline].
Ganz LI. Approach to the Patient with Supraventricular Tachycardia. In: Ganz LI, ed. Management of Cardiac Arrhythmias. ed. Totowa, NJ: Humana; 2002.
Ganz LI, Friedman PL. Supraventricular tachycardia. N Engl J Med. Jan 19 1995;332(3):162-73. [Medline].
Gold MR, Josephson ME. Cardiac arrhythmia: current therapy. Hosp Pract (Minneap). Sep 1 1999;34(9):27-8, 31-2, 35-8 passim. [Medline].
Habibzadeh MA. Multifocal atrial tachycardia: a 66 month follow-up of 50 patients. Heart Lung. Mar-Apr 1980;9(2):328-35. [Medline].
Jazayeri MR, Hempe SL, Sra JS, et al. Selective transcatheter ablation of the fast and slow pathways using radiofrequency energy in patients with atrioventricular nodal reentrant tachycardia. Circulation. Apr 1992;85(4):1318-28. [Medline].
Josephson ME, Zimetbaum PJ, Buxton AE, Marchlinski FE. Tachyarrhythmias. In: Harrison TR, Resnik WR, Isselbacher KJ, et al, eds. Harrison's Online [serial online]. New York, NY: McGraw-Hill; 2001.
Josephson ME, Kastor JA. Supraventricular tachycardia: mechanisms and management. Ann Intern Med. Sep 1977;87(3):346-58. [Medline].
Josephson ME, Wellens HJ. Electrophysiologic evaluation of supraventricular tachycardia. Cardiol Clin. Nov 1997;15(4):567-86. [Medline].
Klein GJ, Sharma AD, Yee R, Guiraudon GM. Classification of supraventricular tachycardias. Am J Cardiol. Aug 31 1987;60(6):27D-31D. [Medline].
Klein GJ, Bashore TM, Sellers TD, Pritchett EL, Smith WM, Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med. Nov 15 1979;301(20):1080-5. [Medline].
Krahn AD, Yee R, Klein GJ, Morillo C. Inappropriate sinus tachycardia: evaluation and therapy. J Cardiovasc Electrophysiol. Dec 1995;6(12):1124-8. [Medline].
Lesh MD, Van Hare GF, Epstein LM, et al. Radiofrequency catheter ablation of atrial arrhythmias. Results and mechanisms. Circulation. Mar 1994;89(3):1074-89. [Medline].
Levy S, Ricard P. Using the right drug: a treatment algorithm for regular supraventricular tachycardias. Eur Heart J. May 1997;18 Suppl C:C27-32. [Medline].
Montoya PT, Brugada P, Smeets J, et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. Eur Heart J. Feb 1991;12(2):144-50. [Medline].
Murdock CJ, Leitch JW, Teo WS, Sharma AD, Yee R, Klein GJ. Characteristics of accessory pathways exhibiting decremental conduction. Am J Cardiol. Mar 1 1991;67(6):506-10. [Medline].
Obel OA, Camm AJ. Supraventricular tachycardia. ECG diagnosis and anatomy. Eur Heart J. May 1997;18 Suppl C:C2-11. [Medline].
Obel OA, Camm AJ. Accessory pathway reciprocating tachycardia. Eur Heart J. May 1998;19 Suppl E:E13-24, E50-1. [Medline].
Orejarena LA, Vidaillet H Jr, DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol. Jan 1998;31(1):150-7. [Medline].
Oren JW 4th, Beckman KJ, McClelland JH, Wang X, Lazzara R, Jackman WM. A functional approach to the preexcitation syndromes. Cardiol Clin. Feb 1993;11(1):121-49. [Medline].
Phillips J, Spano J, Burch G. Chaotic atrial mechanism. Am Heart J. Aug 1969;78(2):171-9. [Medline].
Pieper SJ, Stanton MS. Narrow QRS complex tachycardias. Mayo Clin Proc. Apr 1995;70(4):371-5. [Medline].
Reimold SC. Avoiding drug problems. The safety of drugs for supraventricular tachycardia. Eur Heart J. May 1997;18 Suppl C:C40-4. [Medline].
Rosen KM, Mehta A, Miller RA. Demonstration of dual atrioventricular nodal pathways in man. Am J Cardiol. Feb 1974;33(2):291-4. [Medline].
Scheinman MM. Catheter ablation for cardiac arrhythmias, personnel, and facilities. North American Society of Pacing and Electrophysiology Ad Hoc Committee on Catheter Ablation. Pacing Clin Electrophysiol. May 1992;15(5):715-21. [Medline].
Scher DL, Arsura EL. Multifocal atrial tachycardia: mechanisms, clinical correlates, and treatment. Am Heart J. Sep 1989;118(3):574-80. [Medline].
Siberry GK, Iannone R. The Harriet Lane Handbook: A Manual for Pediatric House Officers. 15th ed. St. Louis, Mo: Mosby-Year Book; 2000.
Strickberger SA, Okishige K, Meyerovitz M, Shea J, Friedman PL. Evaluation of possible long-term adverse consequences of radiofrequency ablation of accessory pathways. Am J Cardiol. Feb 15 1993;71(5):473-5. [Medline].
Sung RJ, Castellanos A, Mallon SM, Bloom MG, Gelband H, Myerburg RJ. Mechanisms of spontaneous alternation between reciprocating tachycardia and atrial flutter-fibrillation in the Wolff-Parkinson-White syndrome. Circulation. Sep 1977;56(3):409-16. [Medline].
Tintinalli JE, Kelen GD, Stapczynski JS. Emergency Medicine: A Comprehensive Study Guide. 5th ed. New York, NY: McGraw Hill; 2000.
Trohman RG. Supraventricular tachycardia: implications for the intensivist. Crit Care Med. Oct 2000;28(10 Suppl):N129-35. [Medline].
Vidaillet HJ Jr, Pressley JC, Henke E, Harrell FE Jr, German LD. Familial occurrence of accessory atrioventricular pathways (preexcitation syndrome). N Engl J Med. Jul 9 1987;317(2):65-9. [Medline].
Waldo AL, Wit AL. Mechanisms of cardiac arrhythmias. Lancet. May 8 1993;341(8854):1189-93. [Medline].
Wellens HJ. Value and limitations of programmed electrical stimulation of the heart in the study and treatment of tachycardias. Circulation. May 1978;57(5):845-53. [Medline].
Wolff L, Parkinson J, White PD. Bundle-branch block with short P-R interval in healthy young people prone to paroxysmal tachycardia. Am Heart J. 1930;5:685-704.
Wood KA, Drew BJ, Scheinman MM. Frequency of disabling symptoms in supraventricular tachycardia. Am J Cardiol. Jan 15 1997;79(2):145-9. [Medline].
Wu D, Denes P, Amat-Y-Leon F, Wyndham CR, Dhingra R, Rosen KM. An unusual variety of atrioventricular nodal re-entry due to retrograde dual atrioventricular nodal pathways. Circulation. Jul 1977;56(1):50-9. [Medline].
Xie B, Thakur RK, Shah CP, Hoon VK. Clinical differentiation of narrow QRS complex tachycardias. Emerg Med Clin North Am. May 1998;16(2):295-330. [Medline].
Fu H, Hu H, Yang Q, Cui K, Chu N, Jiang J. [A retrospective study of 4865 cases of paroxysmal supraventricular tachycardia treated with catheter ablation]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. Jun 2009;26(3):499-503. [Medline].
Further Reading
Keywords
paroxysmal supraventricular tachycardia, PSVT, supraventricular tachycardia, SVT, multifocal atrial tachycardia, MAT, tachyarrhythmia, atrial fibrillation, AF, conduction pathway disturbance, conduction pathway abnormality, conduction pathway anomaly, dysrhythmia, heart condition, heart rhythm problem, atrial tachyarrhythmia, atrioventricular tachyarrhythmia, AV tachyarrhythmia, sinus tachycardia, inappropriate sinus tachycardia, IST, sinusnodal reentranttachycardia, SNRT, atrial tachycardia, atrial flutter, AV tachyarrhythmias, AV nodal reentrant tachycardia, atrioventricular nodal reentrant tachycardia, AVNRT, atrioventricular reentrant tachycardia, AV reentrant tachycardia, AVRT, junctional ectopic tachycardia, JET, nonparoxysmal junctional tachycardia, NPJT, heartfailure, pulmonary edema, myocardial ischemia, myocardial infarction, syncope, sudden death, tachycardia-induced cardiomyopathy, WPW syndrome
